Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?

IQVIA’s Data Advantage Supports Long-Term Growth

IQVIA’s information platform includes roughly 61 petabytes of proprietary data and more than one billion non-identified patient records. Its healthcare-focused technology infrastructure and analytics capabilities allow customers to connect clinical, commercial and real-world information at scale.

That resource base serves more than 10,000 clients and creates a meaningful barrier to entry. Competitors can build software or research capacity, but matching the breadth of IQVIA’s data, industry expertise and established customer relationships would require substantial time and investment.

IQVIA’s Growth Engines Continue to Expand

Research & Development Solutions revenues increased 8.8% year over year in the second quarter, while Commercial Solutions revenues rose 8.6%. Growth was broad-based, with patient solutions, commercial engagement, analytics and consulting contributing alongside increased adoption of artificial intelligence tools.

Those businesses address a market estimated at more than $330 billion. ICON plc ICLR and Medpace Holdings Inc. MEDP also reported positive second-quarter booking and revenue trends, underscoring healthy demand for outsourced clinical-development services while keeping competitive pressure in focus.

IQVIA’s Cash Flow Funds Heavy Buybacks

Second-quarter operating cash flow increased 26% to $558 million, while free cash flow rose 23.3% to $360 million. That cash generation gives IQVIA flexibility to invest in technology, acquisitions and shareholder returns.

IQVIA repurchased $398 million of stock during the quarter and $950 million in the first half of 2026. The company retained $2.82 billion of authorization at June 30, but the pace of future repurchases will depend on cash generation and other capital-allocation priorities.

IQVIA’s Debt and Liquidity Raise Caution

Debt totaled about $16 billion at the end of the second quarter, with net debt of $14.09 billion. The net leverage ratio stood at 3.59 times trailing adjusted EBITDA, leaving the company exposed to interest costs and limiting room for operating setbacks.

The current ratio was about 0.71, below the cited industry level, as current assets of $6.23 billion trailed current liabilities of $8.82 billion. IQVIA does not currently plan to pay a dividend, so shareholder returns remain tied mainly to price appreciation and repurchases.

                                                                          Image Source: Zacks Investment Research

IQVIA’s Valuation Offers a Mixed Signal

IQVIA trades at 13.02X trailing enterprise value to EBITDA. That is below its five-year median and the cited sub-industry multiple, but above the broader medical-sector comparison.

                                                                    Image Source: Zacks Investment Research

                                                                    Image Source: Zacks Investment Research

The discount to its historical valuation may look reasonable, yet it does not eliminate the leverage risk. Pricing pressure, backlog-conversion timing and recent share appreciation could make additional gains more dependent on sustained earnings and cash-flow execution.

IQVIA’s Hold Signal Fits the Trade-Off

IQVIA’s data scale, diversified client base and improving segment growth support the long-term case. High leverage and weak short-term liquidity argue against treating those advantages as a reason for an aggressive entry at any price.

The stock currently carries a Zacks Rank #3 (Hold), which supports patience rather than a forceful buy call. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

IQV’s Value Score of B and VGM Score of B are constructive, while a Growth Score of C and Momentum Score of C point to a more balanced near-term profile.

The combination fits the broader trade-off. IQVIA has improving fundamentals and valuable assets, but investors may prefer to wait for continued debt management, cash-flow progress or a more favorable entry point before taking a larger position.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research